Leader: Federico Carpi (UNIFI); Other collaborator(s):
This task has the following goals: (i) Development of extracorporeal perfusion systems for donor organs, so as to enable ex-vivo investigations on aging at an organ level; this will allow for testing directly on perfused organs the response to drugs normally administered to the elders (e.g., anti-inflammatory, metabolic or immunosuppressive molecules). (ii) Development of cardiac organoids, for in-vitro investigations on aging at a tissue level; this activity has the long-term vision of testing personalised drugs on 3D cellular constructs based on cardiomyocytes that are derived from human induced pluripotent stem cells (iPSC), which can be obtained by harvesting primary cells directly from the patient that requires the personalised drug.
During the concerned period, the research activities have covered the following aspects:
Main policy, industrial and scientific implications:
The research activities concerned by this Task could have the following important implications:
Please see the next reporting period.
During the concerned period, the research activities have covered the following topics:
1) Development of an extracorporeal perfusion device for donor organs: The activities were focused on the design, production, and testing of a new heat exchanger based on Peltier cell technology. The device allowed for smoothly changing the temperature of the perfused organ from 4°C to 37°C, and to reverse the process from 37°C to 4°C, without the use of ice. Tests on ex-vivo animal organs were conducted during the normothermic perfusion phase using the device. The results (which are accepted for publication in the IEEE Open Journal of Engineering in Medicine and Biology), demonstrated the device's ability to rewarm and maintain the organs at a nearly constant temperature (33°C) for an average of 4 hours, without causing the severe damage typically observed in organs stored in ice without perfusion. In these experiments, a 2-hour hypothermic perfusion (4°C) was performed using a commercial machine in combination with ice. The goal of future experiments is to use the developed device for both the phases of the protocol (hypothermic and normothermic), to reduce the number of machines used in the transplant procedure and optimize temperature control, thereby minimizing temperature fluctuations and extending perfusion time to up to 12 hours.
2) Development of cardiac organoids: The activities were focused on the creation of a biocompatible hydrogel that can host human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes, suitable for 3D bioprinting. In particular, a 3D-printable gelatin methacrylate-xanthan gum hydrogel bioink was developed and characterised. Tests with hiPSCs showed the hydrogel’s ability to promote their proliferation within both 2D and 3D cell cultures. The tests also showed that hiPSCs inside hemispheres of the hydrogel were able to differentiate into cardiomyocytes, capable of spontaneous contractions (average frequency of ~0.5 Hz and amplitude of ~2%). Furthermore, bioprinting tests proved the possibility of fabricating 3D constructs of the hiPSC-laden hydrogel, with well-defined line widths (~800 mm). The work was presented at the IDBN 2024 National Congress (26-27 September 2024, Florence, Italy). A research paper on this work was published in the Journal of Functional Biomaterials.
During the concerned period, the research activities covered the following topics:
During the concerned period, the research activities covered the following topics:
1) Development of an extracorporeal perfusion device for donor organs:
Experimental sessions were conducted using the developed perfusion device, confirming the feasibility of the developed retrieval and perfusion protocol. Animal livers, collected from the slaughterhouse in Chiesina Uzzanese (PT) under the supervision of ASL veterinarians, were washed with a physiological solution according to the protocol; after appropriate storage in ice within a thermal container, they were transported to the Simulation LAB at the Surgical Clinics of Careggi Hospital. Following the surgical procedure of cannulating the arterial and venous vessels, the livers were placed in the perfusion machine and subjected to different thermal protocols to evaluate the stability of physiological and chemical parameters. The machine was tested in all its functions (centrifugal pumping, peristaltic pumping, filtering, oxygenation, thermal maintenance, energy consumption). During the experiments, chemical tests were conducted using blood gas analysis (Emogas) to track the time-course of parameters such as dissolved oxygen in the perfusion fluid, lactate levels released by the organ as an indicator of general inflammation, pH, and other specific values. Thanks to endurance experiments lasting over 12 hours, conducted with both hypothermic and normothermic cycles, it was possible to test both the selected components and the logic of the perfusion machine's circulation system. The machine proved to be capable of maintaining thermal, pressure, oxygenation, and filtration parameters within ranges suitable for the survival of a perfused porcine liver. For these initial experiments, a physiological solution was used as the perfusion fluid, yielding better preservation results with hypothermic cycles. For each experiment, a histological sampling campaign was conducted, which in the coming months will allow for the analysis of the quality of the perfused organs using fluorescence immunohistology examinations under different customized thermal protocols.
2) Development of cardiac organoids:
The activities on this topic during the last period had to cope with a severe limitation, due to the breakdown of the 3D bioprinter that had been used so far for this research. As a result, 3D printing was (and still is) prevented. While waiting for the possibility of using the instrumentation again, the research has been focused on investigating commercial biocompatible UV-curable hydrogels (such as LunaGel by Gelomics), as possible suitable carriers for human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. Such cells were found to be viable after mixing with LunaGel, and undergoing droplet deposition and UV curing, so as to obtain 3D (hemispherical-like) structures. This provided evidence that LunaGel can effectively be used with hiPSC-derived cardiomyocytes to create 3D gel structures hosting vital cardiomyocytes.